CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.20
-0.10 (-3.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.30
Open3.30
Bid3.20 x 800
Ask3.30 x 900
Day's Range3.20 - 3.40
52 Week Range2.25 - 5.00
Volume233,132
Avg. Volume230,774
Market Cap182.789M
Beta1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.67
Trade prices are not sourced from all markets
  • Benzinga15 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...

  • PR Newswire15 days ago

    Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254

    HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.

  • PR Newswire15 days ago

    Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody

    Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigational new drug (IND) application for COM701, a first-in-class immuno-oncology therapeutic antibody targeting PVRIG in patients with advanced solid tumors, and informed the Company it may initiate the clinical study. "Today is a significant milestone for Compugen, having received clearance from the FDA to advance our lead immuno-oncology program into the clinic. COM701 is a first-in-class drug opportunity that was developed by Compugen from discovery of the drug target by computer prediction through preclinical development, to IND clearance," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen.

  • When Should You Buy Compugen Ltd (NASDAQ:CGEN)?
    Simply Wall St.20 days ago

    When Should You Buy Compugen Ltd (NASDAQ:CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGM. Less-covered, smallRead More...

  • PR Newswirelast month

    Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants

    Compugen Ltd. (CGEN)(CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors providing for the issuance of approximately 5.3 million of its ordinary shares at a purchase price of $3.95 per share, which represents the closing bid price on June 14, 2018, in a registered direct offering. In connection with the issuance of the ordinary shares, Compugen will also issue warrants to purchase up to approximately 4.3 million additional ordinary shares. The warrants have an exercise price of $4.74 per share, will be exercisable six-months following their issuance and will have a term of five years from the date of issuance.

  • PR Newswirelast month

    Compugen Announces the Appointment of New Board Members

    HOLON, Israel, June 11, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of three new members to its Board of Directors. Mr. Gilead Halevy, founding member and general partner of Kedma Capital Partners, Kinneret Livnat Savitzky, Ph.D., Interim CEO and board member of FutuRx Ltd., and Mr. Sanford (Sandy) Zweifach, founder and CEO of Nuvelution Pharma, Inc. were appointed to Compugen's Board.

  • Market Has Not Yet Noticed Potential in Compugen; Have You?
    Zacks2 months ago

    Market Has Not Yet Noticed Potential in Compugen; Have You?

    Compugen (CGEN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Associated Press2 months ago

    Compugen: 1Q Earnings Snapshot

    On a per-share basis, the Holon, Israel-based company said it had profit of less than 1 cent. The drug developer posted revenue of $10 million in the period. The company's shares closed at $3.33. A year ...

  • PR Newswire2 months ago

    Compugen Reports First Quarter 2018 Results

    HOLON, Israel , May 9, 2018 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You?
    Simply Wall St.2 months ago

    Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You?

    When Compugen Ltd (NASDAQ:CGEN) released its most recent earnings update (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...

  • PR Newswire3 months ago

    Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET

    HOLON, Israel , April 30, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire3 months ago

    Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody

    HOLON, Israel, April 27, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) requested that the Company provide additional CMC information in support of its IND application for COM701, initially submitted in late March 2018. COM701 is a first-in-class immuno-oncology therapeutic antibody targeting PVRIG. FDA recommended a lower starting dose of COM701 for the trial, which now requires a more sensitive COM701 assay detection method for this dose.

  • ACCESSWIRE3 months ago

    Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy

    LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.

  • PR Newswire3 months ago

    Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy

    HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...

  • PR Newswire3 months ago

    Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

    Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program.

  • Reuters3 months ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • Reuters3 months ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?
    Simply Wall St.4 months ago

    At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered, small caps tendRead More...

  • PR Newswire4 months ago

    Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer

    HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. Dr. Adewoye brings to Compugen over two decades of extensive and broad experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia.  As Chief Medical Officer, Dr. Adewoye will play a key role in leading the Company's transition into a clinical stage company, and will assume overall responsibility of Compugen's clinical stage pipeline programs.

  • Simply Wall St.4 months ago

    Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You?

    Compugen Ltd’s (NASDAQ:CGEN) most recent earnings announcement in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Today IRead More...

  • PR Newswire4 months ago

    Compugen to Present at the Cowen and Company 38th Annual Health Care Conference

    HOLON, Israel , March 8, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...

  • ACCESSWIRE5 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018, at 10:00 AM Eastern Time. ...

  • Associated Press5 months ago

    Compugen reports 4Q loss

    The Holon, Israel-based company said it had a loss of 18 cents per share. For the year, the company reported that its loss widened to $37.1 million, or 72 cents per share. The company's shares closed at ...